Article
DNA mismatch repair in cancer immunotherapy
8 Jun 2023
Abstract excerpt
Tumors defective in DNA mismatch repair (dMMR) exhibit microsatellite instability (MSI). Currently, patients with dMMR tumors are benefitted from anti-PD-1/PDL1-based immune checkpoint inhibitor (ICI) therapy. Over the past several years, great progress has been made in understanding the mechanisms by which dMMR tumors respond to ICI, including the identification of mutator phenotype-generated neoantigens,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
